APG Asset Management N.V. Lowers Stake in Elevance Health, Inc. $ELV

APG Asset Management N.V. lowered its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 1.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 192,025 shares of the company’s stock after selling 3,600 shares during the quarter. APG Asset Management N.V. owned about 0.09% of Elevance Health worth $62,047,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of ELV. Nilsine Partners LLC increased its position in Elevance Health by 1.5% during the 3rd quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock valued at $620,000 after buying an additional 29 shares in the last quarter. HBK Sorce Advisory LLC grew its holdings in shares of Elevance Health by 4.4% during the third quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock valued at $260,000 after buying an additional 31 shares during the last quarter. Detalus Advisors LLC increased its position in shares of Elevance Health by 1.8% in the 3rd quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock valued at $558,000 after acquiring an additional 31 shares during the period. Forum Financial Management LP raised its stake in Elevance Health by 1.1% in the 3rd quarter. Forum Financial Management LP now owns 2,971 shares of the company’s stock worth $960,000 after acquiring an additional 33 shares during the last quarter. Finally, Activest Wealth Management lifted its position in Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after acquiring an additional 34 shares during the period. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health Price Performance

Shares of Elevance Health stock opened at $320.65 on Monday. The firm has a market cap of $70.77 billion, a PE ratio of 12.76, a P/E/G ratio of 1.77 and a beta of 0.51. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The business has a 50-day moving average price of $350.23 and a 200 day moving average price of $335.99.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period last year, the company earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Sell-side analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be given a dividend of $1.72 per share. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Tuesday, March 10th. Elevance Health’s dividend payout ratio (DPR) is currently 27.23%.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Truist Financial cut their price objective on Elevance Health from $400.00 to $390.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. UBS Group set a $400.00 price target on shares of Elevance Health in a research report on Thursday, January 29th. Mizuho set a $413.00 price objective on shares of Elevance Health in a report on Friday, January 9th. Wells Fargo & Company cut their price objective on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a research note on Friday, January 30th. Finally, Zacks Research upgraded shares of Elevance Health from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 6th. Twelve equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $390.55.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.